BriaCell Thereapeutics (CVE:BCT) said last week that it named biotechnology veteran Dr. William Williams as its president & CEO effective Nov. 1.
The Berkeley, Calif.-based company’s lead product is a genetically engineered, whole-cell vaccine derived from a human breast tumor cell line. BriaCell suggests that the vaccine may be able to trigger the immune system to recognize and eliminate cancerous cells by encouraging tumor-directed T cell and antibody responses. Results from 2 Phase I trials showed encouraging results in patients with advanced solid tumors, according to BriaCell.
Get the full story at our sister site, Drug Delivery Business News.